|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians显示文摘Pancreatic cancer(PC) would become the second leading cause of cancer death in the near future, despite representing only 3% of new cancer diagnosis. Survival improvement will come from a better knowledge of risk factors, earlier diagnosis, better integration of locoregional and systemic therapies, as well as the development of more efficacious drugs rising from a deeper understanding of disease biology. For patients with unresectable, non-metastatic disease, combined strategies encompassing primary chemotherapy and radiation seems to be promising. In fit patients, new polychemotherapy regimens can lead to better outcomes in terms of slight but significant survival improvement associated with a positive impact on quality of life. The upfront use of these regimes can also increase the rate of radical resections in borderline resectable and locally advanced PC. Second line treatments showed to positively affect both overall survival and quality of life in fit patients affected by metastatic disease. At present, oxaliplatin-based regimens are the most extensively studied. Nonetheless, other promising drugs are currently under evaluation. Presently, in addition to surgery and conventional radiation therapy, new locoregional treatment techniques are emerging as alternative options in the multimodal approach to patients or diseases not suitable for radical surgery. As of today, in contrast with other types of cancer, targeted therapies failed to show relevant activity either alone or in combination with chemotherapy and, thus, current clinical practice does not include them. Up to now, despite the fact of extremely promising results in different tumors, also immunotherapy is not in the actual therapeutic armamentarium for PC. In the present paper, we provide a comprehensive review of the current state of the art of clinical practice and research in PC aiming to offer a guide for clinicians on the most relevant topics in the management of this disease. | Rosella Spadi Federica Brusa Agostino Ponzetti Isabella Chiappino Nadia Birocco Libero Ciuffreda Maria Antonietta Satolli | 2016 | World Journal of Clinical Oncology2016，7，1： | 15 |
| 2 | Gastric cancer:The times they are a-changin'显示文摘Gastric cancer is the third leading cause of cancer death worldwide.Even though during these last decades gastric cancer incidence decreased in Western countries,it remains endemic and with a high incidence in Eastern countries.The survival in advanced and metastatic stage of gastric cancer is still very poor.Recently the Cancer Genoma Atlas Research Network identified four subtypes with different molecular profiles to classify gastric cancer in order to offer the optimal targeted therapies for pre-selected patients.Indeed,the key point is still the selection of patients for the right treatment,on basis of molecular tumor characterization.Since chemotherapy reached a plateau of efficacy for gastric cancer,the combination between cytotoxic therapy and biological agents gets a better prognosis and decreases chemotherapeutic toxicity.Currently,Trastuzumab in combination with platinum and fluorouracil is the only approved targeted therapy in the first line for c-erb B2 positive patients,whereas Ramucirumab is the only approved targeted agent for patients with metastatic gastric cancer.New perspectives for an effective treatment derived from the immunotherapeutic strategies.Here,we report an overview on gastric cancer treatments,with particular attention to recent advances in targeted therapies and in immunotherapeutic approach. | Maria Antonietta Satolli Lucio Buffoni Rosella Spadi Ilaria Roato | 2015 | World Journal of Gastrointestinal Oncology2015，7，11： | 6 |
| 3 | Dietary energy restriction abolishes development of prolactinproducing pituitary tumors in Fischer 344 rats treated with 17 beta-estradiol 显示文摘 | Lemus-Wilson AM Pennington KL | 1998 | Mol Carcinog1998，23，2： | 1 |
| 4 | Dropouts from higher educalion:toward an errpirical model 显示文摘 | SPADY W G | 1972 | Interehang1972，，2： | 1 |
| 5 | Modulation of estrogen action in the rat pituitary and mammary glands by dietary energy consumption 显示文摘 | Harvell DM Lemus- Wilson A | 1999 | J Nutr1999，129，2： | 1 |
| 6 | Estrogeninduced pituitary tumor development in the ACI rat not inhibited by dietary energy restriction 显示文摘 | Pennington KL McComb RD | 1999 | Mol Carcinog1999，26，4： | 1 |
| 7 | Choosing Outcomes of Significance 显示文摘 | Spady W | 1994 | Educa- tional Leadership1994，，6： | 1 |
| 8 | Kinetic constants for receptor-dependent andreceptor-independent low density lipoprotein transport in the tissues of the rat andhamster显示文摘 | Spady DK Meddings SM Dietschy JM | 1986 | J Clin Invest1986，77，5： | 1 |
| 9 | Patterns of injury in children a population based approach显示文摘 | Spady DW Saunders DL Schopflocher DP | 2004 | Pediatrics2004，113，52： | 1 |
| 10 | Endotoxin, TNF, and IL-1 decrease cholesterol 7 alphahydroxylasemRNA levels and activity显示文摘 | Feingold KR Spady DK Pollock AS | 1996 | J Lipid IRes1996，37，2： | 1 |
| 11 | Measles vaccination of infants in a well-vaccinated population 显示文摘 | Carson MM Spady DW Albrecht P | 1995 | Pediatr Infect Dis J1995，14，1： | 1 |
| 12 | Patterns of injury in children : a population-based approach 显示文摘 | Spady DW Saunders DL Sehopflocher DP | 2004 | Pediatrics2004，113，： | 1 |
| 13 | Estrogen action in the regulation of cell proliferation, cell survival, and tumorigenesis in the rat anterior pituitary gland显示文摘 | Thomas J. Spady Rodney D. McComb Dr. James D. Shull | 1999 | Endocrine1999，，3： | 1 |
| 14 | Dropouts from higher education: An interdisciplinary review and synthesis 显示文摘 | Spady W | 1970 | Interchange1970，，1： | 1 |
| 15 | Cell-mediated and antibody immune responses to AIK-C and Connaught monovalent measles vaccine given to 6 month old infants 显示文摘 | Pabst HF Spady DW Carson MM | 1999 | Vaccine1999，17，15： | 1 |
| 16 | Genetic bases of estrogon-induced pituitary growth in an intercross between the ACI and Copenhagen rat strains: dominant Mendelian inheritance of ACI phenotype显示文摘 | Spady TJ PenningtonK McComb RD | 1999 | Endocrinology1999，140，6： | 1 |
| 17 | Pituitary tumorigenesis targeted by the ovine follicle-stimulating hormone beta-subunit gene regulatory region in transgenic mice显示文摘 | Pernasetti F Spady TJ Hall SB | 2003 | Mol Cell Endocrinol2003，203，12： | 1 |
| 18 | Estrogen-induced tumorigenesis in the Copenhagen rat: disparate susceptibilities to development of prolactin-producing pituitary tumors and mammary carcinomas 显示文摘 | Spady TJ Harvell DM Snyder MC | 1998 | Cancer Letters1998，124，1： | 1 |
| 19 | Interaction of dietary saturated and polyunsaturated triglycerides in regulating the processes that determine plasma LDL concentrations in the rat显示文摘 | SPADY D K WOLLETT L A | 1990 | Lipid Res1990，31，： | 1 |
| 20 | Beyond traditional outcome-based education显示文摘 | Spady W G Marshall K J | 1991 | Educational Leadership1991，49，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员